Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Lu AF87908 in Healthy Volunteers and Alzheimer's Disease
NCT04149860Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2019
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AF87908 in Alzheimer's disease (AD) (3 arms), sponsored by Lundbeck. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events, Area Under the Concentration-time Curve from Zero to Time t and 2 more. Started Sep 2019; status: completed.
02
Drugs
Lu AF87908
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04149860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149860.